

REMARKS

The Rejection of Claims 64-72 Under 35 USC §101 Should Be Withdrawn

The Examiner rejected claims 64-72 under 35 USC §101. The Examiner argued that the claimed invention is not supported by either a specific and substantial utility or a well-established utility. The Examiner stated that the utilities asserted in the specification “are not considered to be specific and substantial because neither the specification nor any art of record teaches what biological activities of SEQ ID NO:2 are, how they function, or a specific and well-established utility for SEQ ID NO:2 protein.” The Examiner continued, “the specification fails to teach what kind(s) enzymatic reaction the protein carries out.” In addition, the Examiner stated, “Until some actual and specific activity can be attributed to the SEQ ID NO:2 protein used in the claimed screening assay is incomplete.”

Applicants respectfully traverse the rejection and submit that utilities for the polypeptides which are specific and substantial are in fact set forth in the specification. For example, at page 7, lines 9-10; at page 10, line 28 through page 11, line 14; in Figure 2; and at page 12, line 25, the specification teaches that the 62112 polypeptide is a human protein with an acyl-CoA dehydrogenase domain and acyl-CoA dehydrogenase activity. This is further supported by the studies of Zhang et al. (refer to citation C1 in Supplemental Information Disclosure Statement submitted on January 30, 2004). Zhang et al. described the cloning and characterization of 62112, which they designate acyl-CoA dehydrogenase 9, or ACAD-9 (see alignment of SEQ ID NO:3 and ACAD-9 (GenBank Accession No. BC013354, submitted herewith as Supplemental Information Disclosure Statement Citation No. C2) in Appendix A, showing 100% identity). Zhang et al. teach that 62112 is indeed a human acyl-CoA dehydrogenase, which exhibits acyl-CoA dehydrogenase activity (see Zhang et al., pages 1036-1037, paragraph spanning, and Fig. 5) especially towards stearyl-CoA and palmitoyl-CoA. Thus, contrary to the Examiner's assertion, the specification does indeed teach what kind of enzymatic reaction the protein carries out, and this has been corroborated by others as evidenced by the teachings of Zhang et al. Therefore, the claimed methods pertain to specific molecules, with substantial and specific activities.

The Examiner also asserted that “the specification does not teach a relationship to any specific disease...” and, “does not teach a relationship between the different tissue distribution of the protein to any specific disease...” The Examiner added, “the implicit assertion of anticancer activity for the protein is not substantial.”

Applicants respectfully disagree. For example, the specification at page 3, lines 25-36; at pages 86-90, and in Tables 1 and 2, for example, teaches that the 62112 dehydrogenase molecules can be used to treat cancer and tumors, including those arising from colon, breast, lung or ovarian cells, for example, and that the 62112 dehydrogenase is a useful target for the identification of compounds for the

modulation of cellular proliferation (e.g. cellular proliferative disorders, including tumors arising from colon, breast, lung or ovarian cells). The specification also teaches, for example at pages 86-90 and in Tables 1-2, that the 62112 dehydrogenase is differentially expressed in lung tumors, breast tumors, ovarian tumors, and colon tumors (among others) versus their normal counterpart tissues. Applicants submit that one of ordinary skill in the relevant art would readily understand the relationship of the differential expression of 62112 protein (e.g. expression in tumor vs. normal tissue) and cellular proliferation disorders, (e.g. tumors arising from lung, breast, ovary, and colon tissues). Applicants point out that this differential expression was determined and confirmed by two separate methods (TaqMan mRNA expression and in situ hybridization), further supporting the Applicants assertion of utility in cellular proliferative disorders. Thus, contrary to the Examiner's assertion, the specification does indeed link the polypeptide of the invention to specific cellular proliferative disorders (e.g. tumors arising from lung, breast, ovary, and colon vs. normal respective tissues).

Moreover, Applicants assert that a showing of specific diseases which are in fact demonstrated to be treatable by the invention is not necessary. The Examiner focuses on the specific biological significance and seemingly the required efficacious use of identified compounds as Applicants' requirement to satisfy the utility requirement. Applicants respectfully submit this focus is undue and improper. Still further, the utility of identification of targets for screening for therapeutics in the pharmaceutical industry is a well established recognized utility for molecules useful in biological functions such as those identified and asserted in the present application as useful (e.g. cell growth and proliferation, cancer).

The Examiner appears to assert that the claimed methods require further determination of efficacy or activity *in vivo*. Applicants respectfully point out that the claimed screening methods do not require any *in vivo* step, but rather recite a method of identifying a compound which binds to a 62112 polypeptide, wherein the compound is capable of modulating cellular growth or proliferation of cancer cells *in vitro*.

In summary, Applicants have identified an acyl-CoA dehydrogenase molecule, named 62112, whose activity as an acyl-CoA dehydrogenase has been confirmed by the studies of Zhang et al. In addition, Applicants have demonstrated differential expression of 62112 in tumor versus normal tissues by two independent methods, and have asserted a use for the claimed invention in identifying compounds which are capable of modulating cellular proliferation disorders. Therefore, Applicants submit that the utilities set forth for the 62112 dehydrogenase of the invention are specific and credible. Applicants also submit that the utilities set forth for the 62112 dehydrogenase of the invention are substantial utilities, since the asserted use to identify modulators of cell growth or proliferation using the provided methods constitutes a real world use. Thus, in contrast to the Examiner's assertions, Applicants submit a utility specific, substantial and credible for methods using the 62112 dehydrogenase has in fact been asserted.

Applicants submit the Examiner has not met the requirement to rebut Applicants asserted utility – no evidence specific to demonstrate Applicants' asserted utility is inoperative, not useful, or contradictory to scientific principles has been presented.

Applicants submit that an effective, credible, specific and substantial utility has been properly asserted in the specification as filed. Therefore, Applicants respectfully believe the Examiner's imposition of the present rejection is improper, and as such the rejection under 35 USC §101 should be withdrawn. Applicants respectfully request reconsideration and withdrawal of the rejection of claims 64-72 under 35 USC §101.

**The Rejection of Claims 64-72 Under 35 USC §112, First Paragraph (Enablement)
Should Be Withdrawn**

Claims 64-72 were rejected under 35 USC §112, first paragraph due to lack of satisfying the utility requirement. For the reasons discussed above, Applicants submit the utility requirement has been met and respectfully request reconsideration and withdrawal of the rejection under 35 USC §112, first paragraph.

CONCLUSIONS

In view of the remarks made herein, Applicants respectfully submit that the rejections presented by the Examiner are now overcome and that this application is in condition for allowance. If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned.

This paper is being filed timely as a request for a three month extension of time is filed concurrently herewith. No additional extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

November 9, 2005

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Mario Cloutier


Registration No. 57,225

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-577-3522

Facsimile - 617-551-8820



APPENDIX A

In re application of:	Meyers, Rachel E., et al		
Application No.:	09/945, 326	Group No.:	1642
Filed:	August 31, 2001	Examiner:	Yu, Misook
For:	62112, A NOVEL HUMAN DEHYDROGENASE AND USES THEREOF		

ALIGNMENT of SEQ ID NO:3 from 09/945,326 and ACAD-9 (GenBank Accession No. BC013354)

gb|BC013354|BC013354 Homo sapiens acyl-Coenzyme A dehydrogenase family, member

9, mRNA (cDNA clone MGC:14970 IMAGE:3935925), complete cds.
Length = 2439

Plus Strand HSPs:

Score = 9315 (1403.7 bits), Expect = 0.0, P = 0.0

Identities = 1863/1863 (100%), Positives = 1863/1863 (100%), Strand = Plus / Plus

```
Query:      1 ATGAGCGGCTGCGGGCTCTTCTGCGCACACGCTGCGGCTCGTGCCTGCCGGGGTCTG 60
             |||
Sbjct:     57 ATGAGCGGCTGCGGGCTCTTCTGCGCACACGCTGCGGCTCGTGCCTGCCGGGGTCTG 116

Query:     61 GTGGTCTCTACCGCGAACCGGCGGCTACTGCGCACACAGCCCGCTGTACGAGCTTTCGCC 120
             |||
Sbjct:    117 GTGGTCTCTACCGCGAACCGGCGGCTACTGCGCACACAGCCCGCTGTACGAGCTTTCGCC 176

Query:    121 AAAGAGCTTTTCTTAGGCAAAATCAAGAAGAAAGAGTTTCCCATTTCAGAAAGTTAGC 180
             |||
Sbjct:    177 AAAGAGCTTTTCTTAGGCAAAATCAAGAAGAAAGAGTTTCCCATTTCAGAAAGTTAGC 236

Query:    181 CAAGATGAACTTAATGAAATCAATCAGTTCTTGGGACCCGTGGAAAAATCTTCACTGAA 240
             |||
Sbjct:    237 CAAGATGAACTTAATGAAATCAATCAGTTCTTGGGACCCGTGGAAAAATCTTCACTGAA 296

Query:    241 GAGGTGGACTCCCGAAAAATTGACCAGGAAGGGAAAAATCCAGATGAAACTTTGGAGAAA 300
             |||
Sbjct:    297 GAGGTGGACTCCCGAAAAATTGACCAGGAAGGGAAAAATCCAGATGAAACTTTGGAGAAA 356

Query:    301 TTGAAGAGCCTAGGGCTTTTGGGCTGCAAGTCCCAGAAGAATATGGTGGCCTGGGCTTC 360
             |||
Sbjct:    357 TTGAAGAGCCTAGGGCTTTTGGGCTGCAAGTCCCAGAAGAATATGGTGGCCTGGGCTTC 416

Query:    361 TCCAACACCATGTACTCAAGACTAGGGGAGATCATCAGCATGGATGGGTCCATCACTGTG 420
             |||
Sbjct:    417 TCCAACACCATGTACTCAAGACTAGGGGAGATCATCAGCATGGATGGGTCCATCACTGTG 476

Query:    421 ACCCTGGCAGCGCACCAGGCTATTGGCCTCAAGGGGATCATCTTGGCTGGCACTGAGGAG 480
             |||
Sbjct:    477 ACCCTGGCAGCGCACCAGGCTATTGGCCTCAAGGGGATCATCTTGGCTGGCACTGAGGAG 536

Query:    481 CAGAAAGCCAAATACTTGCCATAAACTGGCGTCCGGGGAGCACATTGCAGCCTTCTGCCTC 540
             |||
Sbjct:    537 CAGAAAGCCAAATACTTGCCATAAACTGGCGTCCGGGGAGCACATTGCAGCCTTCTGCCTC 596

Query:    541 ACGGAGCCAGCCAGTGGGAGCGATGCAGCCTCAATCCGGAGCAGAGCCACACTAAGTGAA 600
             |||
Sbjct:    597 ACGGAGCCAGCCAGTGGGAGCGATGCAGCCTCAATCCGGAGCAGAGCCACACTAAGTGAA 656

Query:    601 GACAAGAAGCACTACATCCTCAATGGCTCCAAGGTCTGGATTACTAATGGAGGACTGGCC 660
             |||
Sbjct:    657 GACAAGAAGCACTACATCCTCAATGGCTCCAAGGTCTGGATTACTAATGGAGGACTGGCC 716

Query:    661 AATATTTTTTACTGTGTTTGCAAAGACTGAGGTCGTTGATTCTGATGGATCAGTGAAAGAC 720
             |||
```

Sbjct:	717	AAATATTTTTACTGTGTTTGGCAAAGACTGAGGTCGTTGATTCTGATGGATCAGTGAAAGAC	776
Query:	721	AAAATCACAGCATTCATAGTAGAAAGAGACTTTGGTGGAGTCACTAATGGGAAACCCGAA	780
Sbjct:	777	AAAATCACAGCATTCATAGTAGAAAGAGACTTTGGTGGAGTCACTAATGGGAAACCCGAA	836
Query:	781	GATAAATTAGGCATTTCGGGGCTCCAACACTTGTGAAGTCCATTTTGAAAACACCAAGATA	840
Sbjct:	837	GATAAATTAGGCATTTCGGGGCTCCAACACTTGTGAAGTCCATTTTGAAAACACCAAGATA	896
Query:	841	CCTGTGGAAAACATCCTTGGAGAGGTCGGAGATGGGTTTAAGGTGGCCATGAACATCCTC	900
Sbjct:	897	CCTGTGGAAAACATCCTTGGAGAGGTCGGAGATGGGTTTAAGGTGGCCATGAACATCCTC	956
Query:	901	AACAGCGGCCCGGTTTCAGCATGGGCAGCGTCGTGGCTGGGCTGCTCAAGAGATTGATTGAA	960
Sbjct:	957	AACAGCGGCCCGGTTTCAGCATGGGCAGCGTCGTGGCTGGGCTGCTCAAGAGATTGATTGAA	1016
Query:	961	ATGACTGCTGAGTACGCCTGCACAAGGAAACAGTTTAACAAGAGGCTCAGTGAATTTGGA	1020
Sbjct:	1017	ATGACTGCTGAGTACGCCTGCACAAGGAAACAGTTTAACAAGAGGCTCAGTGAATTTGGA	1076
Query:	1021	TTGATTTCAGGAGAAATTTGCACTGATGGCTCAGAAGGCTTACGTCATGGAGAGTATGACC	1080
Sbjct:	1077	TTGATTTCAGGAGAAATTTGCACTGATGGCTCAGAAGGCTTACGTCATGGAGAGTATGACC	1136
Query:	1081	TACCTCACAGCAGGGATGCTGGACCAACCTGGCTTTCCCGACTGCTCCATCGAGGCAGCC	1140
Sbjct:	1137	TACCTCACAGCAGGGATGCTGGACCAACCTGGCTTTCCCGACTGCTCCATCGAGGCAGCC	1196
Query:	1141	ATGGTGAAGGTGTTTCAGCTCCGAGGCCGCTGGCAGTGTGTGAGTGAGGCGCTGCAGATC	1200
Sbjct:	1197	ATGGTGAAGGTGTTTCAGCTCCGAGGCCGCTGGCAGTGTGTGAGTGAGGCGCTGCAGATC	1256
Query:	1201	CTCGGGGGCTTGGGCTACACAAGGGACTATCCGTACGAGCGCATACTGCGTGACACCCGC	1260
Sbjct:	1257	CTCGGGGGCTTGGGCTACACAAGGGACTATCCGTACGAGCGCATACTGCGTGACACCCGC	1316
Query:	1261	ATCCTCCTCATCTTCGAGGGAACCAATGAGATTCTCCGGATGTACATCGCCCTGACGGGT	1320
Sbjct:	1317	ATCCTCCTCATCTTCGAGGGAACCAATGAGATTCTCCGGATGTACATCGCCCTGACGGGT	1376
Query:	1321	CTGCAGCATGCCGGCCGCATCCTGACTACCAGGATCCATGAGCTTAAACAGGCCAAAGTG	1380
Sbjct:	1377	CTGCAGCATGCCGGCCGCATCCTGACTACCAGGATCCATGAGCTTAAACAGGCCAAAGTG	1436
Query:	1381	AGCACAGTCATGGATACCGTTGGCCGGAGGCTTCGGGACTCCCTGGGCCGAAGTGTGGAC	1440
Sbjct:	1437	AGCACAGTCATGGATACCGTTGGCCGGAGGCTTCGGGACTCCCTGGGCCGAAGTGTGGAC	1496
Query:	1441	CTGGGGCTGACAGGCAACCATGGAGTTGTGCACCCCAGTCTTGCGGACAGTGCCAACAAG	1500
Sbjct:	1497	CTGGGGCTGACAGGCAACCATGGAGTTGTGCACCCCAGTCTTGCGGACAGTGCCAACAAG	1556
Query:	1501	TTTGAGGAGAACACCTACTGCTTCGGCCGGACCGTGGAGACACTGCTGCTCCGCTTTGGC	1560
Sbjct:	1557	TTTGAGGAGAACACCTACTGCTTCGGCCGGACCGTGGAGACACTGCTGCTCCGCTTTGGC	1616
Query:	1561	AAGACCATCATGGAGGAGCAGCTGGTACTGAAGCGGGTGGCCAACATCCTCATCAACCTG	1620
Sbjct:	1617	AAGACCATCATGGAGGAGCAGCTGGTACTGAAGCGGGTGGCCAACATCCTCATCAACCTG	1676
Query:	1621	TATGGCATGACGGCCGTGCTGTGCGGGGCCAGCCGCTCCATCCGCATTGGGCTCCGCAAC	1680
Sbjct:	1677	TATGGCATGACGGCCGTGCTGTGCGGGGCCAGCCGCTCCATCCGCATTGGGCTCCGCAAC	1736
Query:	1681	CACGACCACGAGGTTCTCTTGGCCAACACCTTCTGCGTGGAAGCTTACTTGCAGAATCTC	1740
Sbjct:	1737	CACGACCACGAGGTTCTCTTGGCCAACACCTTCTGCGTGGAAGCTTACTTGCAGAATCTC	1796
Query:	1741	TTCAGCCTCTCTCAGCTGGACAAGTATGCTCCAGAAAACCTAGATGAGCAGATTAAGAAA	1800

Sbjct: 1797 TTCAGCCTCTCTCAGCTGGACAAGTATGCTCCAGAAAACCTAGATGAGCAGATTAAGAAA 1856
Query: 1801 GTGTCCCAGCAGATCCTTGAGAAGCGAGCCTATATCTGTGCCCACCCTCTGGACAGGACA 1860
|||||
Sbjct: 1857 GTGTCCCAGCAGATCCTTGAGAAGCGAGCCTATATCTGTGCCCACCCTCTGGACAGGACA 1916
Query: 1861 TGC 1863
|||
Sbjct: 1917 TGC 1919